Marchward (Page 3)

Digest №2: How You Can Improve Your Cancer Survival by Mastering the Mental Aspect of It

2026, week 8: How a mindset shift can help you live longer and better despite cancer, an easier way for you to get into contact with us, and a correction issued this week.

Digests

Merlin L. Marquard

Feb 28, 2026 — 4 min read

Correction: Recent Retraction of a Case Study on Fenbendazole Use in Cancer Patients

A paper, which we've referenced in the past, has been retracted. We thus issue a correction as to keep you on the bleeding edge of scientific insight.

Corrections

Merlin L. Marquard

Feb 25, 2026 — 2 min read

Digest №1: A Way to Serve Your Outliving Cancer Better and Consideration with Anti-Cancer Ketogenic Diet

2026, week 8: Ketogenic diets are powerful but imperfect anti-cancer tools, alkalisation shows anti-cancer efficacy in human patients.

Digests

Merlin L. Marquard

Feb 23, 2026 — 4 min read

On the Gamification of Cancer Survival

A cancer diagnosis is one of the most daunting and stressful events in a cancer patient's life. So, how can we frame this challenge to make it a bit less stressful and dire?

Essays

Merlin L. Marquard

Feb 14, 2026 — 6 min read

In Defence of Classical Care and Classically Trained Physicians and Nurses

The limitations of classical care in no way are a condemnation of it. Much more their understanding can enable us to use classical care more effectively and with less frustration.

Essays

Merlin L. Marquard

Feb 11, 2026 — 3 min read

Anecdotal Success in Using a Soft Pharmaceutical Regimen to Lower the IL-6 Status in a Patient with Malignant Pleural Mesothelioma

4 months of treatment with a pharmaceutical plan formulated to suppress IL-6 over-expression in one patient has shown first success. Continuation and reproducibility of the effect remain to be seen.

Reports

Merlin L. Marquard

Feb 5, 2026 — 5 min read

Correction: Ganoderma Lucidum Suppresses IL-6 only Inconsistently with Variance between Experiments

In a prior article, information about discrepancies in the effect of Ganoderma lucidum on IL-6 profiles. This is a correction to that article.

Corrections

Merlin L. Marquard

Jan 23, 2026 — 2 min read

On The Therapeutic Potential of Tocilizumab in IL-6-Positive Cancers

IL-6 is an immune signaller misappropriated by many cancer types to engender immune senescence and proliferative auto-signalling. Disrupting this misappropriation can help overcome IL-6-positive cancers.

Essays

Merlin L. Marquard

Jan 17, 2026 — 4 min read

Archive

Digest №2: How You Can Improve Your Cancer Survival by Mastering the Mental Aspect of It

Correction: Recent Retraction of a Case Study on Fenbendazole Use in Cancer Patients

Digest №1: A Way to Serve Your Outliving Cancer Better and Consideration with Anti-Cancer Ketogenic Diet

On the Gamification of Cancer Survival

In Defence of Classical Care and Classically Trained Physicians and Nurses

Anecdotal Success in Using a Soft Pharmaceutical Regimen to Lower the IL-6 Status in a Patient with Malignant Pleural Mesothelioma

Correction: Ganoderma Lucidum Suppresses IL-6 only Inconsistently with Variance between Experiments

On The Therapeutic Potential of Tocilizumab in IL-6-Positive Cancers

Stay abreast